Natural Capsules

Which are the latest news on Natural Capsules?

Why is Natural Capsules Ltd falling/rising?

As of 05-Sep, the stock price of Natural Capsules Ltd is declining to 217.05, down 3.98% after a trend reversal. Despite earlier gains, increased volatility and reduced investor participation indicate ongoing challenges for the stock.

As of 05-Sep, the stock price of Natural Capsules Ltd is falling, currently at 217.05, which represents a decrease of 9.0 or 3.98%. This decline follows a trend reversal after two consecutive days of gains. Despite opening the day with a gain of 4.84% and reaching an intraday high of Rs 237, the stock experienced significant volatility, trading within a wide range of Rs 22.25, and hitting a low of Rs 214.75, which is a decrease of 5%.<BR><BR>Additionally, the stock has underperformed its sector by 1.81% today, and there has been a notable drop in investor participation, with delivery volume falling by 83.5% compared to the 5-day average. While the stock is trading above its moving averages over various periods, the high volatility and decreased investor engagement suggest that the recent price movements are contributing to the current decline in stock value.

Who are in the management team of Natural Capsules?

The management team of Natural Capsules includes Laxminarayan Moondra, Satyanarayan Mundra, C P Rangachar, Sunil L Mundra, Sushil Kumar Mundra, Jyothi Mundra, Pramod Kasat, Shilpa Burman, and Shirish Gundopant Belapure, who oversee the company's governance and strategic direction.

The management team of Natural Capsules includes the following individuals:<BR><BR>1. **Laxminarayan Moondra** - Whole-time Director<BR>2. **Satyanarayan Mundra** - Whole-time Director<BR>3. **C P Rangachar** - Chairman & Independent Director<BR>4. **Sunil L Mundra** - Managing Director<BR>5. **Sushil Kumar Mundra** - Director<BR>6. **Jyothi Mundra** - Director<BR>7. **Pramod Kasat** - Independent Director<BR>8. **Shilpa Burman** - Company Secretary & Compliance Officer<BR>9. **Shirish Gundopant Belapure** - Independent Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Natural Capsules do?

Natural Capsules Ltd is a micro-cap Indian manufacturer of hard capsule shells, known for introducing vegetarian capsules and being the second-largest producer of gelatin capsules in the country. As of June 2026, the company reported net sales of 49 Cr and a net loss of 4 Cr.

Overview:<BR>Natural Capsules Ltd is a leading manufacturer of hard capsule shells in India, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>History:<BR>Natural Capsules Ltd was incorporated in 1993 and has since established itself as a prominent player in the capsule manufacturing sector. The company introduced vegetarian capsules to the Indian market and is recognized as the second-largest manufacturer of gelatin capsules in the country. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 49 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: -4 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 230 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.50<BR>- Return on Equity: -9.45%<BR>- Price to Book: 0.97<BR><BR>Contact Details:<BR>Address: Trident Towers 4th Floor No 23, 100Feet Road Jayanagar IIBlock Bangalore Karnataka : 560011<BR>Tel: 91-080-26671571/26671573/26671581<BR>Email: company.sec@naturalcapsules.com<BR>Website: http://www.naturalcapsules.com

Who are the peers of the Natural Capsules?

Natural Capsules' peers include Aarey Drugs, Nectar Lifesci., Kerala Ayurveda, Sanjiv.Parant., Coral Labs., Oxygenta Pharma, Brooks Lab., Accretion Pha., and Sat Kartar Life, with varying management risks and growth rates. Aarey Drugs has the highest 1-year return at 44.47%, while Kerala Ayurveda has the lowest at -63.87%, and Natural Capsules reports a return of 8.63%.

Peers: The peers of Natural Capsules are Aarey Drugs, Nectar Lifesci., Kerala Ayurveda, Sanjiv.Parant., Coral Labs., Oxygenta Pharma, Brooks Lab., Accretion Pha., and Sat Kartar Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Sat Kartar Life, while Good management risk is found at Accretion Pha. Average management risk is present at Nectar Lifesci., and Below Average management risk is noted at Aarey Drugs, Kerala Ayurveda, Coral Labs., Brooks Lab., and Oxygenta Pharma. In terms of Growth, Excellent growth is seen at Accretion Pha. and Good growth at Sanjiv.Parant. while Below Average growth is reported at Aarey Drugs, Nectar Lifesci., Kerala Ayurveda, Coral Labs., Brooks Lab., and Oxygenta Pharma. For Capital Structure, Excellent capital structure is noted at Sanjiv.Parant. and Coral Labs., Good capital structure at Accretion Pha., and Below Average capital structure at Aarey Drugs, Nectar Lifesci., Kerala Ayurveda, Brooks Lab., and Oxygenta Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aarey Drugs at 44.47%, while the lowest is Kerala Ayurveda at -63.87%. Natural Capsules has a 1-year return of 8.63%, which is significantly higher than Kerala Ayurveda but lower than Aarey Drugs. Additionally, Oxygenta Pharma, Brooks Lab., and Kerala Ayurveda have negative six-month returns.

How big is Natural Capsules?

As of 31st August, Natural Capsules Ltd has a market capitalization of 230.00 Cr, with net sales of 190.71 Cr and a net loss of 19.35 Cr over the latest four quarters. Shareholder's funds are 221.64 Cr, and total assets are valued at 421.53 Cr as of March 2026.

As of 31st August, Natural Capsules Ltd has a market capitalization of 230.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Natural Capsules reported Net Sales of 190.71 Cr. However, the company faced a loss of 19.35 Cr in Net Profit during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's Funds stand at 221.64 Cr, while Total Assets are valued at 421.53 Cr.

Should I buy, sell or hold Natural Capsules Ltd?

Are Natural Capsules Ltd latest results good or bad?

Natural Capsules Ltd's latest results are concerning, showing a net loss of ₹3.45 crores for the fourth consecutive quarter despite achieving record revenue of ₹58.45 crores. The significant decline in operating margins and negative return on equity indicate ongoing operational challenges.

Natural Capsules Ltd's latest results indicate a challenging situation for the company. In the fourth quarter of FY26, the company reported a net loss of ₹3.45 crores, marking its fourth consecutive quarter of losses. This is a significant decline compared to the profit of ₹0.36 crores reported in the same quarter last year, representing a staggering deterioration of over 1,058%.<BR><BR>On a more positive note, the company achieved its highest quarterly revenue of ₹58.45 crores, reflecting a 54.83% increase from the previous quarter and a 29.98% increase year-on-year. However, this revenue growth has not translated into profitability, as the operating margin fell sharply to 2.28% from 9.76% a year earlier. Additionally, the return on equity (ROE) has turned negative at -5.34%, indicating that the company is currently destroying shareholder value.<BR><BR>Overall, while the revenue growth may seem encouraging, the persistent losses, collapsing margins, and negative ROE highlight significant operational challenges that overshadow the positive aspects of the results. The financial outlook appears concerning, suggesting that the company is in a precarious position.

When is the next results date for Natural Capsules Ltd?

The next results date for Natural Capsules Ltd is 12 August 2026.

The next results date for Natural Capsules Ltd is scheduled for 12 August 2026.

Is Natural Capsules overvalued or undervalued?

As of November 14, 2025, Natural Capsules is considered overvalued and risky, with concerning financial metrics such as a PE ratio of -16.93 and an EV to EBITDA of 37.39, significantly underperforming compared to competitors like Sun Pharma and Cipla, and reflecting a negative stock performance of -28.65% over the past year.

As of 14 November 2025, the valuation grade for Natural Capsules has moved from expensive to risky, indicating a significant shift in the company's perceived value. Based on the analysis, Natural Capsules is currently considered overvalued. The company displays a PE ratio of -16.93, an EV to EBITDA of 37.39, and a Price to Book Value of 0.87, which are concerning metrics compared to its peers.<BR><BR>In comparison to notable competitors, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Cipla maintains a more attractive PE ratio of 22.72 and an EV to EBITDA of 16.08. These ratios highlight that Natural Capsules is not only underperforming relative to its peers but also suggests a lack of investor confidence reflected in its negative stock performance over the past year, with a return of -28.65% compared to a 9.00% gain in the Sensex.

How has been the historical performance of Natural Capsules?

Natural Capsules experienced fluctuating financial performance, with net sales increasing to 169.21 Cr in March 2025 but a decline in profitability, as profit after tax fell to 0.62 Cr. Total assets grew to 419.35 Cr, indicating growth in sales and assets despite challenges in profitability.

Answer:<BR>The historical performance of Natural Capsules shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Natural Capsules reported net sales of 169.21 Cr in March 2025, an increase from 155.42 Cr in March 2024, but a decrease from 172.37 Cr in March 2023. The total operating income followed a similar pattern, reaching 169.21 Cr in March 2025. Raw material costs rose to 86.88 Cr in March 2025 from 84.00 Cr in March 2024, while total expenditure increased to 151.69 Cr in March 2025. Operating profit (PBDIT) decreased to 18.22 Cr in March 2025 from 21.86 Cr in March 2024, leading to a profit before tax of 2.79 Cr in March 2025, down from 8.05 Cr the previous year. The profit after tax also fell to 0.62 Cr in March 2025 from 5.55 Cr in March 2024. Total assets grew to 419.35 Cr in March 2025, up from 376.53 Cr in March 2024, while total liabilities also increased to 419.35 Cr. Cash flow from operating activities showed a positive trend with 26.00 Cr in March 2025, compared to -8.00 Cr in March 2024. Overall, the company's financial performance reflects both growth in sales and assets, but challenges in profitability in the most recent year.

Who are the top shareholders of the Natural Capsules?

The top shareholders of Natural Capsules include Tajos Investments Private Limited with 12.12%, followed by Tarinika Management LLP at 3.22%, and individual investors holding a collective 33.09%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Natural Capsules are primarily the promoters, with Tajos Investments Private Limited holding the highest stake at 12.12%. In terms of public shareholders, Tarinika Management LLP is the largest, owning 3.22%. Additionally, individual investors collectively hold 33.09% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

What is the technical trend for Natural Capsules?

As of June 4, 2025, Natural Capsules show a neutral technical stance with mixed signals: mildly bullish weekly indicators contrast with bearish monthly trends.

As of 4 June 2025, the technical trend for Natural Capsules has changed from mildly bearish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The weekly Bollinger Bands are bullish, contrasting with the monthly which is mildly bearish. Daily moving averages show a mildly bearish trend. The KST is mildly bullish on the weekly but bearish on the monthly, and Dow Theory supports a mildly bullish view on both weekly and monthly time frames. The OBV is bullish for both weekly and monthly periods. Overall, the current technical stance is neutral, with mixed signals across different indicators.

Has Natural Capsules declared dividend?

Natural Capsules Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 20, 2023. Despite the dividend declaration, the company has experienced negative total returns in the short to medium term, but has shown strong recovery over the longer 4 to 5-year periods.

Natural Capsules Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.79%, with a dividend return of 0%, resulting in a total return of -13.79%.<BR><BR>Over the past year, the price return was -10.27%, with a dividend return of 0%, leading to a total return of -10.27%.<BR><BR>In the 2-year period, the price return was -26.91%, with a dividend return of 0.27%, culminating in a total return of -26.64%.<BR><BR>For the 3-year period, the price return was -44.67%, with a dividend return of 0.50%, resulting in a total return of -44.17%.<BR><BR>In the 4-year period, the price return was 63.49%, with a dividend return of 2.01%, leading to a total return of 65.5%.<BR><BR>Over the last 5 years, the price return was 432.19%, with a dividend return of 7.21%, resulting in a total return of 439.4%.<BR><BR>Overall, while Natural Capsules Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant declines in the short to medium term, but a strong recovery over the longer 4 to 5-year periods.